Tests IDP-023 alone and with antibody drugs in advanced blood cancers
Tests IDP-023, alone or with other drugs, in adults with advanced lymphoma or myeloma.
Key facts
- Who runs it
- Indapta Therapeutics, INC.
- Where
- Atlanta, Cleveland, Fairfax, Houston, Lake Mary, Los Angeles, Minneapolis, Nashville, New York, Portland, Providence, and Winston-Salem, United StatesSee the 12 sites
- Trial code
- Registry title
- IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 128 people, planned
- Started
- 25 Oct 2023
- Expected to end
- 31 Dec 2029
- Type of study
- Interventional, 6 groups
- Treatments tested
- IDP-023
- Rituximab
- Daratumumab
- Interleukin-2
- Cyclophosphamide
- Fludarabine
- Mesna
- Isatuximab
- Record updated
- 3 June 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced multiple myeloma or non-Hodgkin lymphoma that came back or did not respond to earlier treatment.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Multiple myeloma that needs systemic therapy and came back or did not respond. Or non-Hodgkin lymphoma that came back or did not respond.
- Earlier treatment
- Multiple myeloma: at least 3 earlier lines of therapy. Non-Hodgkin lymphoma: at least 2 earlier lines of systemic chemotherapy did not work.
Main reasons for not taking part
- Impaired heart function or a history of serious heart disease
- HIV infection, active hepatitis B infection, or hepatitis C infection
- Active SARS-CoV-2 infection
- Untreated cancer spread to the central nervous system, the epidural space or the brain
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- For MM patients: Documented diagnosis of MM requiring systemic therapy and relapsed and/or refractory (R/R) disease after ≥ 3 prior lines of therapy
- For NHL patients: R/R disease and failed ≥ 2 lines of systemic chemotherapy
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Life expectancy of greater than 12 weeks per the Investigator
Who cannot take part
- Impaired cardiac function or history of clinical significant cardiac disease
- Human immunodeficiency virus (HIV) infection, active hepatitis B infection, or hepatitis C infection
- Active SARS-CoV-2 infection
- Has untreated central nervous system, epidural tumor metastasis, or brain metastasis
Where in United States
- Emory University HospitalAtlanta, United StatesContact: Indapta Therapeutics, Inc.Taking people
- University Hospitals ClevelandCleveland, United StatesContact: Indapta Therapeutics, Inc.Taking people
- NEXT Oncology- VirginiaFairfax, United StatesContact: Blake PattersonTaking people
- University of Texas - MD Anderson Cancer CenterHouston, United StatesContact: Christy AllenTaking people
- Florida Cancer Specialists and Research Institute - Lake Mary Cancer CenterLake Mary, United StatesContact: Indapta Therapeutics, Inc.No longer taking part
- Valkyrie Clinical TrialsLos Angeles, United StatesContact: Myo ZawTaking people
- University of MinnesotaMinneapolis, United StatesContact: Kayla Wagenmann, MN, RN, PHNTaking people
- SCRI Oncology PartnersNashville, United StatesContact: Briana SmithTaking people
- NYP/Weill Cornell Medical CenterNew York, United StatesContact: Indapta Therapeutics, Inc.No longer taking part
- Providence Cancer Institute Franz ClinicPortland, United StatesContact: Indapta Therapeutics, Inc.No longer taking part
- Rhode Island HospitalProvidence, United StatesContact: Stephen DonnellyTaking people
- Atrium Health Wake Forest BaptistWinston-Salem, United StatesContact: Catalina Gonzalez-PinzonTaking people
About the trial
What the trial wants to find out
This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without isatuximab, daratumumab or rituximab to evaluate the safety, tolerability and preliminary antitumor activity in patients with advanced hematologic cancers.
The 6 groups in the trial
- Phase 1: Single Agent IDP-023 - Single DoseTreatment being tested
NHL or MM patient treated with a single dose of IDP-023 monotherapy
Treatment: IDP-023, Cyclophosphamide, Fludarabine, and Mesna
- Phase 1: Single Agent IDP-023 - Multiple DosesTreatment being tested
NHL and MM patients treated with multiple doses of IDP-023 monotherapy
Treatment: IDP-023, Cyclophosphamide, Fludarabine, and Mesna
- Phase 1: Single Agent IDP-023 - Multiple Doses with IL-2Treatment being tested
NHL and MM patients treated with multiple doses of IDP-023 monotherapy
Treatment: IDP-023, Interleukin-2, Cyclophosphamide, Fludarabine, and Mesna
- Phase 2: Combination IDP-023 plus rituximabTreatment being tested
NHL patients treated with multiple doses of IDP-023 in combination with rituximab
Treatment: IDP-023, Rituximab, Interleukin-2, Cyclophosphamide, Fludarabine, and Mesna
- Phase 2: Combination IDP-023 plus daratumumabTreatment being tested
MM patients treated with multiple doses of IDP-023 in combination with daratumumab
Treatment: IDP-023, Daratumumab, Interleukin-2, Cyclophosphamide, Fludarabine, and Mesna
- Phase 2: Combination IDP-023 plus isatuximabTreatment being tested
MM patients treated with multiple doses of IDP-023 in combination with isatuximab
Treatment: IDP-023, Interleukin-2, Cyclophosphamide, Fludarabine, Mesna, and Isatuximab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- Plain-language title
- Tests IDP-023 alone and with antibody drugs in advanced blood cancersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 3 June 2025